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ABSTRACT 
 
 The authors researched associations of chemokines genes polymorphisms (+1931А/Т MIP1β, A/G I-
TAC (rs4512021), -403A/G RANTES , C/G MCP1(rs2857657), -801G/A SDF1) with parameters of humoral 
immunity of 238 patients with chronic glomerulonephritis and 462 individuals of a control group. It has been 
revealed that the marker of increased level of IgG under chronic glomerulonephritis is +1931ТТ MIP1β, and 
high concentrations of IgA during aggravation period are associated with - 801AA, - 801GА SDF1. 
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INTRODUCTION 
 
Among parenchymatous kidney diseases chronic glomerulonephritis lies in a principal place. Among 
nephrological diseases chronic glomerulonephritis (CGN) takes more than 35% [1, 2]. It is evident that this is 
the most often-met type of pathologic process in kidneys which is one of the most widespread causes of  
chronic renal failure (which requires haemodialysis and kidney transplantation for curing) [3]. Prevalence rate 
and chronic disease end-stages incidence rate  increase consistently in different regions of the world [4, 5].         
 
According to experimental and clinical data, an important role in CGN progress is played by 
chemokines [6]. Clinical genetic works dedicated to molecular genetic aspects of CGN are rare in Russia and 
touch mainly the spectrum of vasoactive hormones genes, tumour necrosis factors, integral membrane 
proteins and some interleukins [7, 8]. Researches of the role of chemokines genes polymorphous markers 
regarding CGN have not been carried out yet. Whereas chemokines, being chemoattractants, play an 
important role in the progress of inflammatory reactions in an organism and also immuno-inflammatory 
processes under chronic glomerulonephritis [9].        
 
Due to this, lately researchers take an increasing interest in chemokines genes polymorphous markers 
under kidney diseases, classifying them as possible glomerulopathies risk genetic factors. In pursuance of the 
foregoing, in this work we have carried out the investigation of chemokines genetic polymorphisms (+1931А/Т 
MIP1β, A/G I-TAC (rs4512021), -403A/G RANTES , C/G MCP1(rs2857657), -801G/A SDF1) associations with 
parameters of humoral immunity of patients with chronic glomerulonephritis. 
 
MATERIALS AND METHODS 
 
We carried out the analysis of chemokines genes polymorphisms of 700 persons: 238 patients with 
chronic glomerulonephritis (average age 39.58±14.58 years old, varied from 15 to 76 years old) and 462 
individuals of a control group (42.20±6.28 years old, varied from 18 to 79 years old, p>0.05). The sample of 
patients and the control group included individuals of Russian ethnicity, natives of Central Black Earth region of 
Russia, being not related to each other. Patients were included into the patients group only after diagnosing of 
the disease and confirming the diagnosis with the help of clinical and laboratory instrumental methods of 
examination. Clinical laboratory examination of patients was carried out housed by nephrology department of 
Belgorod region clinical hospital.   
 
During the period of blood sampling (questioning), when the patients were passing through hospital 
treatment for the term from two to four weeks, level of immunoglobulins IgA, IgM, IgG was estimated via 
enzyme-linked immunoassay (ELISA), using blood serum samples and standard sets according to a 
manufacturer’s manual.     
 
General clinical examination of patients included careful study of medical history, physical 
examination, complete blood count, common urine analysis with microscopic evaluation of urinary sediment, 
estimation of daily proteinuria, research of biochemical parameters of blood (total protein, albumin, protein 
fractions creatinine, uric acid, urea, cholesterol).     
    
Exclusionary criteria  for the group of patients with CGN were diabetes mellitus (in anamnesis or 
found as a result of examination), hypertension.    
 
As the research material we used venous blood – 8-9 ml from a proband’s median cubital vein. 
Extraction of genomic DNA from peripheral blood was performed with the help of standard methods [10]. 
 
Analysis of all loci was carried out with the help of the method of DNA synthesis polymerase chain 
reaction, using standard oligonucleotide primers and probes [11, 12, 13].    
 
Genotyping of DNA markers (+1931А/Т MIP1β, A/G I-TAC (rs4512021), -403A/G RANTES , C/G 
MCP1(rs2857657), -801G/A SDF1) was carried out via analysis of alleles discrimination with the help of the 
method of Tag Man probes (Tag Man). Associations of alleles and genotypes of the studied DNA-markers with 
arterial hypertension of the patients with chronic glomerulonephritis were estimated with the help of analysis 
of cross tables 2x2 calculating the criterion 2 with Yates correction for continuity and odds ratio (OR) with 
ISSN: 0975-8585 
November - December 2014  RJPBCS   5(6)  Page No. 1363 
95% confidence intervals (CI). For studying of parameters of glomerular filtration rate and creatinine level we 
used median (Me) and interquartile range (Q25-Q75), and for comparative analysis we used Mann-Whitney 
test. (“STATISTICA 6.0”). 
 
RESULTS 
 
We examined 238 patients with chronic glomerulonephritis and 462 individuals of a control group. 
Main characteristics of the examined patients with chronic glomerulonephritis and the control group are 
presented in table 1. It should be noted that the group of CGN patients had much higher levels of IgA and IgG 
than the control group (p<0.001). 
 
Table 1: Characteristics of the subjects from the case and control groups 
 
Characteristics Cases Controls 
Total 
Males 
Females 
Age, yrs  
Weight, kg 
Height, cm 
SBP, mm Hg 
DBP, mm Hg 
Creatinine, μmol/L 
GFR, ml/min 
IgA, g/l 
IgM, g/l 
IgG, g/l 
238 
127 (53.4%)* 
111 (46.6%)* 
39.58 ± 14.58* 
63.4 ± 2.1* 
165.4 ± 3.4* 
148.4 ± 26.5** 
92.7 ± 14.0** 
337.2 ± 44.1** 
28,2±1,8 
3,75±0,14** 
2,950,13 
18,85±0,56** 
304 
125 (51.86%) 
116 (46.64%) 
42.20 ± 6.28 
67.4 ± 1.7 
168.6 ± 2.7 
128.1 ± 4.4 
82.2 ± 2.0 
130.4 ± 7.8 
81,6±3,4 
2,98±0,15 
2,800,20 
12,42±0,73 
 
Note: *p>0.05; **p<0.001. 
 
In the course of analysis of immunoglobulins concentration of the CGN patients, depending on 
presence and intensity of chronic renal failure (CRF), it was found that, firstly, CGN patients without CRF differ 
from the control group only in a high level of IgG (20.28±0.85g/l against 12.42 ±0.74g/l in the control group, р< 
0.001). Secondly, CGN patients with CRF differ from the control group considerably in the level of analyzed 
immunoglobulins: concentration of IgA (3.96±0.18 g\l) and IgG (16.94 ±0.69g/l) is much higher, and content of 
IgМ (2.43 ±0.11g/l) is lower than in the control group.  
 
We found connections of genetic polymorphisms +1931 A/T MIP1β and  
-801G/A SDF1 with the immunoglobulins level of the CGN patients. Individuals with the genotype +1931 ТТ 
MIP1β had the G immunoglobulin concentration which was equal to 22.022.02 g/l and was credibly higher 
than of patients with genotypes  +1931 AА and +1931 AT MIP1β (18.530.59 g/l, p=0.05). 
 
We revealed differences in the nature of associations of chemokines molecular genetic markers with 
immunoglobulin concentration in case of patients with different degrees of the process activity (disease-free 
survival and aggravation) and in case of patients depending on presence of chronic renal failure (CRF). Patients 
with chronic glomerulonephritis aggravation have a high level of IgA (4.990.67 g/l) if they have genotypes – 
801AA and - 801GA SDF1 , as compared to patients with a genotype - 801 GG SDF1 (2.950.27 g/l, р=0.01). We 
revealed connections of genetic polymorphism +1931А/Т MIP1β with concentration of IgG in the group of 
patients without CRF: individuals with a genotype +1931ТТ MIP1β had G immunoglobulin concentration 
equaled to 25.581.62 g/l and it was 1.3 times higher than of the patients with genetic markers +1931АА and 
+1931АТ MIP1β (19.860.89 g/l, р=0.02). 
 
SPECULATION 
 
We found connection of the genotype +1931 ТТ MIP1β with a high level of Ig G of the CGN patients. 
Macrophage inflammatory protein (MIP 1β), along with chemoattractant properties, induces adherence of 
human’s circulating lymphocytes to endothelium *14+ and due to this play an important role in the 
inflammatory cytokines cascade progress in an organism.   
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At the same time, it has been found that the polymorphous genetic marker -801 G/A SDF1 is 
associated with humoral immunity peculiarities of the CGN patients. Patients with genotypes -801 АА and -801 
GA SDF1 have a high level of immunoglobulin А in the aggravation period. 
 
SDF1, being a pre-B-cells growth promotant, conditions intensification of homing of some types of 
stem cells into affected organs (including kidneys), proliferation stimulation, intensification of adhesion and 
motility of cells in a pathologic focus [15], and that plays an important role in the progress of immuno-
inflammatory reactions in glomerular apparatus of kidneys.        
 
CONCLUSION 
 
Thus, the work’s results allow us to conclude that the concentrations of A and G immunoglobulins of 
the patients are 1.3 – 1.5 times higher than the control group’s parameters (р<0.001) and are interconnected 
with the chronic renal failure progress. The marker of an increased level of IgG under chronic 
glomerulonephritis is +1931ТТ MIP1β, and high concentrations of IgA in the aggravation period are associated 
with - 801AA, - 801GА SDF1. 
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